U of M Researcher Awarded Prestigious Grant to Study Drug-Induced Blood Thickening
A University of Montreal researcher has been awarded a prestigious grant to investigate a possibly dangerous side effect of certain medications. Dr. Natasha Szuber, an Associate professor of Clinical Medicine, has been awarded the ASH Scholar Award, a $150,000 grant from the American society of Hematology (ASH). This highly competitive award supports early-career researchers in the United States and Canada who are making meaningful contributions to the understanding and treatment of blood diseases.
Dr. Szuber’s research focuses on secondary erythrocytosis (ES),a condition characterized by an abnormally high number of red blood cells. This overproduction of red blood cells thickens the blood, increasing the risk of blood clots, heart attacks, and strokes.
Her project, titled “Clinical Predictors and Prognostic Impact of Drug-Induced Secondary Erythrocytosis: Bridging the Gaps,” aims to identify individuals at risk of developing drug-induced ES, understand the mechanisms behind its progress, and assess its impact on patient outcomes. Dr. Szuber will also evaluate the effectiveness of various therapeutic interventions.
This groundbreaking research will establish evidence-based guidelines for managing drug-induced ES.The findings will have a direct impact on patient care by informing clinical recommendations,monitoring strategies,and treatment plans. By disseminating these results within the medical community, Dr. Szuber’s work has the potential to substantially improve patient care and outcomes.
Decoding Drug-Induced Blood Thickening: An Interview with Dr. Natasha Szuber
Time.news Editor: Dr. Szuber, congratulations on receiving the prestigious ASH Scholar Award. Can you tell us about your groundbreaking research on drug-induced secondary erythrocytosis (ES)?
Dr. Natasha Szuber: Thank you! Secondary erythrocytosis (ES) occurs when an abnormally high number of red blood cells develop. This thickening of the blood increases the risk of serious complications like blood clots, heart attacks, and strokes. While this condition is becoming more common, we still lack a clear understanding of who is at risk and how to best manage it. My research aims to bridge those gaps.
Time.news Editor: This sounds like a critical area of research. What specifically will your project explore?
Dr. Natasha Szuber: My project, titled “Clinical Predictors and Prognostic Impact of Drug-Induced Secondary Erythrocytosis: Bridging the Gaps,” has three main goals. First, we will identify the specific medications and patient characteristics that increase the risk of developing drug-induced ES.Secondly, we will investigate the underlying mechanisms behind this condition.
we will assess the long-term impact of drug-induced ES on patient outcomes and evaluate the effectiveness of various treatment approaches.
Time.news Editor: How will your findings ultimately help patients?
Dr. natasha Szuber: By clearly identifying who is at risk, understanding the triggers, and evaluating treatment options, we aim to develop evidence-based guidelines for managing drug-induced ES. This will empower doctors to make informed decisions about monitoring and treatment, ultimately improving patient care and reducing the risk of serious complications.
Time.news Editor: What are the potential implications of your work for the pharmaceutical industry?
Dr. Natasha Szuber: Awareness of drug-induced ES could lead to changes in prescribing practices and the progress of safer alternatives. The pharmaceutical industry may also invest in research to develop medications that effectively manage this condition.
Time.news Editor: any words of advice for patients who are concerned about symptoms or the risks associated with drug-induced ES?
Dr. Natasha Szuber: It’s critically important to be aware of the potential for blood thickening as a side effect of medications. if you experience symptoms such as shortness of breath, fatigue, dizziness, or headache, especially when taking new medications, please consult your doctor. Early detection and intervention are key to managing drug-induced ES and preventing complications.
